Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19.

OBJECTIVE: To assess the prevalence, characteristics and prognostic value of pulmonary hypertension (PH) and right ventricular dysfunction (RVD) in hospitalised, non-intensive care unit (ICU) patients with coronavirus disease 2019 (COVID-19).
METHODS: This single-centre, observational, cross-sectional study included 211 patients with COVID-19 admitted to non-ICU departments who underwent a single transthoracic echocardiography (TTE). Patients with poor acoustic window (n=11) were excluded. Clinical, imaging, laboratory and TTE findings were compared in patients with versus without PH (estimated systolic pulmonary artery pressure >35 mm Hg) and with versus without RVD (tricuspid annular plane systolic excursion <17 mm or S wave <9.5 cm/s). The primary endpoint was in-hospital death or ICU admission.
RESULTS: A total of 200 patients were included in the final analysis (median age 62 (IQR 52-74) years, 65.5% men). The prevalence of PH and RVD was 12.0% (24/200) and 14.5% (29/200), respectively. Patients with PH were older and had a higher burden of pre-existing cardiac comorbidities and signs of more severe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (radiological lung involvement, laboratory findings and oxygenation status) compared with those without PH. Conversely, patients with RVD had a higher burden of pre-existing cardiac comorbidities but no evidence of more severe SARS-CoV-2 infection compared with those without RVD. The presence of PH was associated with a higher rate of in-hospital death or ICU admission (41.7 vs 8.5%, p<0.001), while the presence of RVD was not (17.2 vs 11.7%, p=0.404).
CONCLUSIONS: Among hospitalised non-ICU patients with COVID-19, PH (and not RVD) was associated with signs of more severe COVID-19 and with worse in-hospital clinical outcome. TRIAL REGISTRATION NUMBER: NCT04318366. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Introduction

Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), characterised by prominent pulmonary involvement.1 Preliminary pathological findings demonstrate lung oedema, thickening of alveolar septa, inflammatory infiltrates and vascular congestion also in the early phase of the disease.2 Similarly, chest computed tomograpy (CT) studies showed lung abnormalities in asymptomatic SARS-CoV-2-infected individuals.3 Lung parenchymal damage and altered pulmonary haemodynamics may determine pulmonary hypertension (PH) and secondary right ventricular (RV) involvement in patients with COVID-19, even in non-advanced disease stages, as a consequence of hypoxic vasoconstriction of the pulmonary circulation,4 use of positive end-expiratory pressure (PEEP) in mechanical ventilation,5 pulmonary endothelial injury,6 and local inflammatory thrombotic or thromboembolic processes.7 Of note, early studies reported myocardial injury in approximately 20%–30% of hospitalised patients with COVID-198 9; this subclinical cardiac involvement could be explained, at least in part, by PH and RV impairment. Preliminary data suggest that the actual prevalence of PH in patients with COVID-19 may be around 13%, but its prognostic role remains unclear.10 On the contrary, reduced RV longitudinal strain was found as a powerful predictor of higher mortality in patients with COVID-19.11 Hence, our aim was to describe the prevalence, characteristics and prognostic impact of PH and RV involvement in a cohort of hospitalised, non-critically ill patients with COVID-19.

Methods

Study design and study population

This single-centre, observational, cross-sectional study was conducted at a large tertiary centre (San Raffaele Scientific Institute) in Milan, Italy. Within an institutional, centralised, prospective, all-comers registry collecting clinical, laboratory, biological and imaging data on all hospitalised patients with COVID-19 (COVID-BioB), the two co-first authors designed this substudy. The COVID-BioB study was registered on ClinicalTrials.gov (NCT04318366). Patients admitted to non-intensive care unit (ICU) departments with an established diagnosis of COVID-19 (according to current WHO criteria)12 were evaluated for inclusion in the study. All COVID-19 dedicated non-ICU departments (according to our institution rearrangement13) were screened for patient enrolment. Patients were included and evaluated with a single transthoracic echocardiography (TTE) between 24 March and 29 April 2020, up to a prespecified study sample size of 200 patients with analysable TTE data. Subjects with non-adequate transthoracic acoustic window (non-analysable TTE data) were not included in the final analysis. Patients were grouped according to the presence or absence of PH and right ventricular dysfunction (RVD) at TTE assessment.

Patients or the public were not involved in the design, conduct, reporting or dissemination plans of our research.

Equipment, echocardiographic protocol and data collection

Eight authors (MP, LB, AB, VP, FC, MG, GI and AN) performed all TTEs included in this report on a voluntary basis. All physicians were provided with personal protection equipment according to current WHO standards and local institutional protocols, including FFP2 mask or equivalent, double gowns, double pair gloves and eye protection goggles.14 A dedicated echocardiographic machine was used to obtain echocardiographic data (Philips iE33, Philips Healthcare, Eindhoven, The Netherlands) in non-ICU COVID-19 departments. Images were obtained according to a prespecified acquisition protocol, specifically focusing on pulmonary haemodynamics, RV morphology and RV function according to current guidelines.15 16

Two operators simultaneously entered the patients’ room for echocardiographic examination and data collection. Measures were obtained in real time during image acquisition and noted in a case report form to limit overall exposure time. The dedicated TTE machine was cleaned and disinfected before leaving the COVID-19 departments. Images were stored in the hospital’s centralised server after TTE acquisition to allow offline postprocessing. Echocardiographic data were collected in a dedicated electronic database, along with relevant clinical, laboratory and imaging variables. Laboratory data were collected at the time of TTE (same day); if unavailable at the time of TTE, laboratory data obtained within 5 days before TTE were collected. Chest X-ray (CXR) imaging and contrast-enhanced chest CT scan (when performed according to standard clinical practice) were also analysed within the same time window.

Definitions and study endpoints

According to the latest international recommendations, RVD was defined as either tricuspid annular plane systolic excursion (TAPSE) of <17 mm or tissue Doppler imaging S wave (S’ wave) of <9.5 cm/s.15 Systolic pulmonary artery pressure (SPAP) was estimated with the following formula: SPAP=4×tricuspid regurgitation (TR) peak velocity2+right atrial pressure (RAP);16 PH was defined as SPAP >35 mm Hg. The estimation of RAP (central venous pressure) and TR grading were performed according to current guidelines.16 17

The degree of hypoxaemia at hospital admission was assessed by means of the arterial partial pressure of oxygen to fraction of inspired oxygen ratio (PaO2/FiO2), according to established criteria.12 18 At time of TTE, the pulse oximetric saturation to fraction of inspired oxygen ratio (SpO2/FiO2) was used to estimate oxygenation status.19 A CXR severity score was used to grade the extent of radiographical lung involvement, as previously described.20

The primary outcome of interest was the composite of in-hospital all-cause mortality or ICU admission. Secondary outcomes of interest were the two individual endpoints of in-hospital all-cause mortality and ICU admission, hospital discharge, need of invasive mechanical ventilation, need of extracorporeal membrane oxygenation and sepsis.

Statistical analyses

Continuous variables are presented as medians and IQRs and were compared with the Mann-Whitney U test (non-normally distributed continuous data). Categorical variables are presented as numbers and percentages and were compared with the χ2 test or Fisher’s exact test (as appropriate). Primary and secondary outcomes of interest were compared between patients with or without PH and between patients with or without RVD. The impact of variables of interest on the primary endpoint was adjusted for relevant covariates by means of multivariable binary logistic regression. Considering the low number of events, a limited number of covariates were entered in the multivariable model (in order to avoid overfitting). Results of logistic regression are reported as adjusted OR (ORadj) and 95% CI; the Hosmer-Lemeshow (H-L) goodness-of-fit test and C-statistic were used to confirm good calibration and discrimination of the multivariable model. The composite of in-hospital all-cause mortality or ICU admission was also compared between groups using the Kaplan-Meier method (log-rank test).

All reported p values are two-sided, and a p value <0.05 was considered statistically significant.

Statistical analyses were performed using Stata version 13.0 (Stata Corp., College Station, Texas).

Results

A total of 211 patients with COVID-19 hospitalised in non-ICU departments were included in the study; TTE was not feasible in 11 patients because of unsuitable acoustic window. Hence, a total of 200 patients were assessed with TTE and included in the final analysis.

Baseline patient characteristics

Baseline clinical characteristics are reported in table 1. The median age was 62 (IQR 55–74) years, and 65.5% of the patients were men. The median time from symptom onset to hospital admission was 7 (3–10) days, and the median PaO2/FiO2 on hospital admission was 243 (132–314). At TTE evaluation, PH was observed in 24 patients (12.0%), whereas RVD was observed in 29 patients (14.5%); 8 patients (4.0%) had both PH and RVD.

Table 1

Baseline clinical characteristics

	Overall(n=200)	PH(n=24)	No PH(n=176)	P value	RVD(n=29)	No RVD(n=171)	P value
Age (years)	62 (55–74)	76 (67–82)	62 (54–72)	<0.001	65 (55–76)	62 (54–74)	0.813
Male sex	131/200 (65.5)	12/24 (50.0)	119/176 (67.6)	0.089*	20/29 (69.0)	111/171 (64.9)	0.671*
BMI (kg/m2)	25.7 (24.2–28.8)	24.2 (22.1–27.3)	25.9 (24.2–29.3)	0.059	27.5 (24.8–29.0)	25.4 (23.8–28.6)	0.068
Smoking				0.067†			1.000†
Prior smoking	33/200 (16.5)	8/24 (33.3)	25/176 (14.2)		5/29 (17.2)	28/171 (16.4)
Current smoking	8/200 (4.0)	0/24 (0.0)	8/176 (4.6)		1/29 (3.5)	7/171 (4.1)
Dyslipidaemia	45/200 (22.5)	2/24 (8.3)	43/176 (24.4)	0.057†	3/29 (10.3)	42/171 (24.6)	0.099†
Diabetes mellitus				0.049†			0.228†
Non-insulin-dependent	28/200 (14.0)	5/24 (20.8)	23/176 (13.1)		3/29 (10.3)	25/171 (14.6)
Insulin-dependent	9/200 (4.5)	3/24 (12.5)	6/176 (3.4)		3/29 (10.3)	6/171 (3.5)
Hypertension	84/200 (42.0)	16/24 (66.7)	68/176 (38.6)	0.009*	11/29 (37.9)	73/171 (42.7)	0.631*
Family history of CAD	15/200 (7.5)	1/24 (4.2)	14/176 (8.0)	1.000†	4/29 (13.8)	11/171 (6.4)	0.241†
Prior MI	17/200 (8.5)	4/24 (16.7)	13/176 (7.4)	0.129†	7/29 (24.1)	10/171 (5.9)	0.005†
Prior PCI	13/200 (6.5)	1/24 (4.2)	12/176 (6.8)	1.000†	3/29 (10.3)	10/171 (5.9)	0.408†
Prior CABG	6/200 (3.0)	2/24 (8.3)	4/176 (2.3)	0.153†	5/29 (17.2)	1/171 (0.6)	<0.001†
Prior valve intervention	4/200 (2.0)	0/24 (0.0)	4/176 (2.3)	1.000†	4/29 (13.8)	0/171 (0.0)	<0.001†
Prior AF or flutter	22/200 (11.0)	10/24 (41.7)	12/176 (6.8)	<0.001†	9/29 (31.0)	13/171 (7.6)	0.001†
Prior HF diagnosis	7/200 (3.5)	4/24 (16.7)	3/176 (1.7)	0.004†	5/29 (17.2)	2/171 (1.2)	0.001†
Known cardiomyopathy	5/200 (2.5)	3/24 (12.5)	2/176 (1.1)	0.013†	4/29 (13.8)	1/171 (0.6)	0.002†
Prior stroke or TIA	9/200 (4.5)	2/24 (8.3)	7/176 (4.0)	0.295†	2/29 (6.9)	7/171 (4.1)	0.621†
Peripheral artery disease	13/200 (6.5)	3/24 (12.5)	10/176 (5.7)	0.193†	2/29 (6.9)	11/171 (6.4)	1.000†
CKD stages IV–V (eGFR ≤30 mL/min/1.73 m2)	12/200 (6.0)	5/24 (20.8)	7/176 (4.0)	0.007†	1/29 (3.5)	11/171 (6.4)	1.000†
Dialysis	3/200 (1.5)	1/24 (4.2)	2/176 (1.1)	0.320†	0/29 (0.0)	3/171 (1.8)	1.000†
COPD	11/200 (5.5)	4/24 (16.7)	7/176 (4.0)	0.030†	3/29 (10.3)	8/171 (4.7)	0.202†
History of cancer	32/200 (16.0)	4/24 (16.7)	28/176 (15.9)	1.000†	4/29 (13.8)	28/171 (16.4)	1.000†
Known autoimmune disease	9/200 (4.5)	1/24 (4.2)	8/176 (4.6)	1.000†	3/29 (10.3)	6/171 (3.5)	0.126†
Time from symptoms onset to hospital admission (days)	7 (3–10)	7 (3–9)	8 (3–11)	0.224	5 (3–8)	8 (4–11)	0.034
PaO2/FiO2 on hospital admission	243 (132–314)	210 (85–286)	248 (147–317)	0.060	238 (153–276)	245 (131–317)	0.241
200 < PaO2/FiO2≤300	72/187 (38.5)	11/23 (47.8)	61/164 (37.2)	0.193†	15/27 (55.6)	57/160 (35.6)	0.169†
100 < PaO2/FiO2≤200	33/187 (17.7)	3/23 (13.0)	30/164 (18.3)		3/27 (11.1)	30/160 (18.8)
PaO2/FiO2≤100	30/187 (16.0)	6/23 (26.1)	24/164 (14.6)		5/27 (18.5)	25/160 (15.6)
PaCO2 on hospital admission	32 (29–36)	31 (27–37)	32 (29–36)	0.475	34 (30–37)	32 (29–36)	0.412

Data are presented as n/N (%) or median (Q25–Q75).

Bold values represent significant p values.

*χ2 test.

†Fisher’s exact test.

AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HF, heart failure; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary angioplasty; PH, pulmonary hypertension; RVD, right ventricular dysfunction; TIA, transient ischaemic attack.

Patients with PH were older compared with patients without PH (76 (67–82) vs 62 (54–72) years, p<0.001) and had more frequently underlying comorbidities, including diabetes mellitus (p=0.049), hypertension (p=0.009), chronic kidney disease stages IV–V (p=0.007) and chronic obstructive pulmonary disease (p=0.030). Selected cardiac comorbidities were present more often in the PH group, including prior atrial fibrillation or flutter (p<0.001), prior heart failure (p=0.004) and known cardiomyopathy (p=0.013). A non-significant trend towards lower PaO2/FiO2 on hospital admission was observed in patients with PH (210 (85–286) vs 248 (147–317), p=0.060).

Patients with RVD had more frequently underlying cardiac comorbidities compared with patients without RVD, including prior myocardial infarction (p=0.005), prior coronary artery bypass graft (p<0.001), prior valve intervention (p<0.001), prior atrial fibrillation or flutter (p=0.001), prior heart failure (p=0.001) and known cardiomyopathy (p=0.002). Age and PaO2/FiO2 on hospital admission were similar between RVD and no RVD groups. Time from symptom onset to hospital admission was significantly longer in patients without RVD (p=0.034).

Radiological and laboratory findings

Table 2 depicts CXR and laboratory findings. Multiple and bilateral lung infiltrates were observed at CXR in 87.5% and 82.5% of patients, respectively.

Table 2

CXR and laboratory findings

	Overall(n=200)	PH(n=24)	No PH(n=176)	P value	RVD(n=29)	No RVD(n=171)	P value
CXR findings
Multiple lung infiltrates	175/200 (87.5)	23/24 (95.8)	152/176 (86.4)	0.322†	25/29 (86.2)	150/171 (87.7)	0.766†
Bilateral lung infiltrates	165/200 (82.5)	21/24 (87.5)	144/176 (81.8)	0.774†	23/29 (79.3)	142/171 (83.0)	0.625*
Right lung severity score (0–4)	1 (1–2)	2 (2–3)	1 (1–2)	<0.001	1 (1–2)	1 (1–2)	0.987
Left lung severity score (0–4)	1 (1–2)	3 (2–3)	1 (1–2)	<0.001	2 (1–2)	1 (1–2)	0.567
Final severity score (0–8)	3 (2–4)	5 (3–7)	3 (2–4)	<0.001	3 (2–5)	3 (2–4)	0.568
Final severity score ≥4	77/200 (38.5)	17/24 (70.8)	60/176 (34.1)	0.001*	13/29 (44.8)	64/171 (37.4)	0.449*
Laboratory findings
Leucocytes (*109/L)	7.2 (5.5–9.8)	9.0 (7.6–12.2)	7.0 (5.3–9.5)	0.003	7.1 (5.7–8.4)	7.2 (5.4–10.0)	0.552
Lymphocytes (*109/L)	1.2 (0.9–1.8)	0.9 (0.7–1.2)	1.2 (1.0–1.8)	0.001	1.2 (1.0–1.7)	1.2 (0.9–1.8)	0.910
Haemoglobin (g/dL)	12.3 (10.9–13.7)	12.3 (10.5–14.0)	12.4 (10.9–13.7)	0.829	12.8 (11.4–14.4)	12.3 (10.7–13.5)	0.126
Platelets (*109/L)	270 (201–367)	212 (173–294)	282 (214–370)	0.029	283 (192–394)	269 (210–365)	0.819
Creatinine (mg/dL)	0.9 (0.8–1.2)	1.0 (0.8–1.7)	0.9 (0.8–1.1)	0.223	0.9 (0.8–1.1)	0.9 (0.7–1.2)	0.576
C reactive protein (mg/L)	38.1 (13.3–93.5)	106.2 (17.2–147.5)	36.3 (12.6–81.3)	0.011	18 (4.0–45.9)	42.0 (16.4–95.4)	0.019
D-dimer (µg/mL)	1.2 (0.5–2.9)	3.4 (0.6–6.8)	1.1 (0.5–2.5)	0.013	0.7 (0.5–1.5)	1.3 (0.5–3.5)	0.075
Interleukin-6 (pg/mL)	41 (21–97)	120 (39–185)	39 (18–84)	0.003	42 (26–157)	40 (19–96)	0.360
Ferritin (ng/mL)	1032 (591–1638)	1107 (538–2596)	1027 (593–1618)	0.941	1128 (526–1679)	1019 (591–1638)	0.863
Lactate dehydrogenase (U/L)	328 (259–452)	419 (350–560)	321 (254–442)	0.003	376 (286–516)	326 (255–443)	0.161
Total bilirubin (mg/L)	0.6 (0.4–0.9)	0.8 (0.5–1.0)	0.6 (0.4–0.9)	0.109	0.6 (0.4–1.0)	0.6 (0.4–0.9)	0.406
Aspartate transaminase (U/L)	43 (31–61)	51 (32–64)	42 (31–61)	0.358	46 (32–63)	42 (30–61)	0.304
Alanine transaminase (U/L)	41 (27–71)	35 (25–61)	43 (27–73)	0.300	56 (28–78)	40 (26–67)	0.243
High-sensitivity troponin T (ng/L)	13.6 (6.0–30.0)	43.5 (15.3–75.5)	12.0 (5.8–25.0)	0.001	24.3 (11.4–67.1)	12.7 (5.5–24.6)	0.006
Creatine phosphokinase (U/L)	85 (47–139)	105 (68–294)	81 (47–135)	0.062	123 (61–175)	76 (44–129)	0.010
NT-proBNP (pg/mL)	256 (89–707)	1408 (610–2963)	194 (85–577)	<0.001	625 (143–1481)	209 (85–604)	0.011

Data are presented as n/N (%) or median (Q25–Q75).

Bold values represent significant p values.

*χ2 test.

†Fisher’s exact test.

CXR, chest X-ray; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PH, pulmonary hypertension; RVD, right ventricular dysfunction.

Patients with PH had higher CXR severity score compared with patients without PH (5 [3-7] vs 3 [2-4]; p<0.001), and a higher proportion of CXR severity score of ≥4 was observed in the PH group (70.8 vs 34.1%, p=0.001). A total of 56/200 patients (28.0%) underwent contrast-enhanced chest CT scan (data not presented in tables); among these, pulmonary thromboembolism was more frequently observed among patients with PH (7/9, 77.8%) compared with patients without PH (9/47, 19.2%; p=0.001).

Compared with patients without RVD, patients with RVD had similar CXR severity score and a similar proportion of CXR severity score of ≥4. Among patients with available contrast-enhanced chest CT scan, the prevalence of pulmonary thromboembolism was not significantly different between patients with RVD (1/8, 12.5%) compared with those without RVD (15/48, 31.3%; p=0.416).

Regarding laboratory findings, patients with PH had higher leucocyte count (p=0.003), lower lymphocyte count (p=0.001) and lower platelet count (p=0.029) compared with patients without PH. The PH group showed higher levels of D-dimer (p=0.013), C reactive protein (p=0.011), interleukin-6 (p=0.003), lactate dehydrogenase (p=0.003), high-sensitivity troponin T (p=0.001) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) (p<0.001).

Compared with patients without RVD, patients with RVD had lower levels of C reactive protein (p=0.019) and higher levels of high-sensitivity troponin T (p=0.006), creatine phosphokinase (p=0.010) and NT-proBNP (p=0.011).

Data on clinical setting at the time of TTE and TTE findings are reported in table 3. In the overall population, the proportion of patients with suboptimal transthoracic window (yet sufficient for TTE data analysis) was 44.0%. The median time from hospital admission to TTE was 7 (3–13) days.

Table 3

Echocardiographic assessment

	Overall (n=200)	PH (n=24)	No PH (n=176)	P value	RVD (n=29)	No RVD (n=171)	P value
Clinical setting at time of TTE
Window quality				0.528*			0.616*
Good	112/200 (56.0)	12/24 (50.0)	100/176 (56.8)		15/29 (51.7)	97/171 (56.7)
Sufficient/suboptimal	88/200 (44.0)	12/24 (50.0)	76/176 (43.2)		14/29 (48.3)	74/171 (43.3)
Time from hospital admission to TTE (days)	7 (3–13)	8 (4–11)	7 (3–13)	0.901	8 (3–10)	7 (3–13)	0.862
SBP (mm Hg)	120 (107–128)	113 (105–121)	120 (110–130)	0.156	115 (100–120)	120 (107–130)	0.239
HR (beats/min)	80 (70–88)	80 (75–90)	80 (70–88)	0.296	78 (74–85)	80 (70–88)	0.724
NIV				<0.001†			0.905†
Intermittent cycles (no NIV during TTE)	38/200 (19.0)	5/24 (20.8)	33/176 (18.5)		5/29 (17.2)	33/171 (19.3)
NIV during TTE	24/200 (12.0)	9/24 (37.5)	15/176 (8.5)		4/29 (13.8)	20/171 (11.7)
SpO2/FiO2	283 (167–394)	166 (110–280)	312 (193–448)	<0.001	286 (188–457)	283 (167–354)	0.622
TTE findings
Basal RVEDD (mm)	36 (32–40)	42 (38–48)	36 (32–39)	<0.001	38 (35–42)	36 (32–40)	0.129
Mid RVEDD (mm)	30 (26–33)	37 (31–40)	30 (26–32)	<0.001	32 (30–36)	30 (26–33)	0.028
RV length (mm)	65 (60–73)	70 (60–73)	65 (60–72)	0.488	69 (61–72)	65 (60–73)	0.561
Proximal RVOT diameter (mm)	30 (27–34)	30 (27–36)	30 (27–34)	0.893	30 (27–39)	30 (27–34)	0.364
TAPSE (mm)	22 (20–25)	20 (17–22)	22 (20–25)	0.004	16 (15–19)	23 (20–25)	<0.001
S’ TDI (cm/s)	13 (11–15)	12 (9–13)	13 (11–15)	0.004	9 (8–9)	14 (12–15)	<0.001
Tricuspid regurgitation				<0.001†			0.015†
None/trivial	123/200 (61.5)	0/24 (0.0)	123/176 (69.9)		14/29 (48.3)	100/171 (63.7)
Mild	63/200 (31.5)	12/24 (50.0)	51/176 (29.0)		9/29 (31.0)	54/171 (31.6)
Moderate	14/200 (7.0)	12/24 (50.0)	2/176 (1.1)		6/29 (20.7)	8/171 (4.7)
Severe	0/200 (0.0)	0/24 (0.0)	0/176 (0.0)		0/29 (0.0)	0/171 (0.0)
RA area (cm2)	14 (12–16)	16 (13–21)	14 (11–16)	0.062	14 (11–21)	14 (12–16)	0.725
SPAP (mm Hg)	29 (23–33)	42 (39–47)	25 (22–30)	<0.001	30 (25–40)	28 (23–31)	0.064
LVEF (%)	59 (55–63)	59 (56–65)	59 (55–63)	0.900	59 (50–63)	59 (56–63)	0.085
CVP (mm Hg)				<0.001†			0.006†
0–5	152/200 (76.0)	10/24 (41.7)	142/176 (80.7)		17/29 (58.6)	135/171 (79.0)
5–10	38/200 (19.0)	8/24 (33.3)	30/176 (17.1)		7/29 (24.1)	31/171 (18.1)
10–20	10/200 (5.0)	6/24 (25.0)	4/176 (2.3)		5/29 (17.2)	5/171 (2.9)

Data are presented as n/N (%) or median (Q25–Q75).

Bold values represent significant p values.

*χ2 test.

†Fisher’s exact test.

CVP, central venous pressure; HR, heart rate; LVEF, left ventricular ejection fraction; NIV, non-invasive ventilation; PEEP, positive end-expiratory pressure; PH, pulmonary hypertension; RV, right ventricle; RVD, right ventricular dysfunction; RVEDD, right ventricle end-diastolic diameter; RVOT, right ventricle outflow tract; SBP, systolic blood pressure; SPAP, systolic pulmonary artery pressure; S’TDI, tissue Doppler imaging S wave; TAPSE, tricuspid annular plane systolic excursion; TTE, transthoracic echocardiography.

Patients with PH were more frequently treated with non-invasive ventilation (NIV) compared with patients without PH (intermittent cycle—no NIV during TTE 20.8 vs 18.5%, NIV during TTE 37.5 vs 8.5%; p<0.001). The SpO2/FiO2 ratio at time of TTE was significantly lower in the PH group (166 (110–280) vs 312 (193–448), p<0.001). The proportion of patients treated with NIV and SpO2/FiO2 ratio was similar between the RVD and the no RVD groups.

In terms of TTE findings, patients with PH had significantly higher basal RV end-diastolic diameter (42 (38–48) vs 36 (32–39) mm, p<0.001) and mid RV end-diastolic diameter (37 (31–40) vs 30 (26–32) mm, p<0.001), and lower TAPSE (20 (17–22) vs 22 (20–25) mm, p=0.004) and S’ wave (12 (9–13) vs 13 (11–15) cm/s, p=0.004) compared with patients without PH. The median estimated SPAP in the PH group was 42 (39–47) mm Hg. Patients with PH had higher degrees of TR (p<0.001) and estimated central venous pressure (p<0.001) compared with patients without PH. Left ventricular ejection fraction was similar between the PH and no PH groups (p=0.900).

Compared with patients without RVD, patients with RVD had higher mid RV end-diastolic diameter (32 (30–36) vs 30 (26–33) mm, p=0.028). Median TAPSE and S’ wave in the RVD group were 16 (15–19) mm and 9 (8–9) cm/s, respectively. Degrees of TR (p=0.015) and estimated central venous pressure (p=0.006) were higher in the RVD group. Left ventricular ejection fraction was not significantly different between the RVD and no RVD groups (p=0.085).

In-hospital clinical outcomes

After a median follow-up of 9 (4–14) days, 19 patients died (9.5%); 7 patients required ICU admission (3.5%); 135 patients were discharged (67.5%); and 40 patients were still hospitalised in a non-ICU department (20.0%). As shown in table 4, the rate of all-cause death or ICU admission (primary endpoint) was 12.5% (25 patients).

Table 4

In-hospital clinical outcomes

	Overall(n=200)	PH(n=24)	No PH(n=176)	P value	RVD(n=29)	No RVD(n=171)	P value
All-cause death or ICU admission	25/200 (12.5)	10/24 (41.7)	15/176 (8.5)	<0.001†	5/29 (17.2)	20/171 (11.7)	0.404*
All-cause death	19/200 (9.5)	8/24 (33.3)	11/176 (6.3)	<0.001†	4/29 (13.8)	15/171 (8.8)	0.489†
ICU admission	7/200 (3.5)	2/24 (8.3)	5/176 (2.8)	0.199†	1/29 (3.5)	6/171 (3.5)	1.000†
Need of invasive ventilation	7/200 (3.5)	2/24 (8.3)	5/176 (2.8)	0.199†	1/29 (3.5)	6/171 (3.5)	1.000†
Need of ECMO	2/200 (1.0)	0/24 (0.0)	2/176 (1.1)	1.000†	0/29 (0.0)	2/171 (1.2)	1.000†
Sepsis	14/200 (7.0)	1/24 (4.2)	13/176 (7.4)	1.000†	1/29 (3.5)	13/171 (7.6)	0.697†
Discharge	135/200 (67.5)	7/24 (29.2)	128/176 (72.7)	<0.001*	17/29 (58.6)	118/171 (69.0)	0.270*

Data are presented as n/N (%).

Bold values represent significant p values.

*χ2 test.

†Fisher’s exact test.

ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; PH, pulmonary hypertension; RVD, right ventricular dysfunction.

The primary endpoint was significantly higher among patients with PH compared with patients without PH (41.7 vs 8.5%, p<0.001), driven by a higher incidence of all-cause mortality in the PH group (33.3 vs 6.3%, p<0.001). The proportion of discharged patients was significantly lower in the PH group (29.2 vs 72.7%, p<0.001). Figure 1 shows the Kaplan-Meier curves for the composite of in-hospital all-cause mortality or ICU admission in patients with or without PH, confirming the significantly higher incidence in the pH group (log-rank p value of <0.001).

Figure 1

In-hospital all-cause mortality or ICU admission in COVID-19 with or without PH and RVD. The figure shows Kaplan-Meier curves for in-hospital all-cause mortality or ICU admission in patients with COVID-19 with versus without PH (A) and with versus without RVD (B). ICU, intensive care unit; PH, pulmonary hypertension; RVD, right ventricular dysfunction.

The rate of the primary endpoint (17.2 vs 11.7%; p=0.404) and of all-cause mortality (13.8 vs 8.8%; p=0.489) were not significantly different in patients with or without RVD. The proportion of discharged patients was similar between patients with or without RVD (58.6 vs 69.0%; p=0.270). As shown in figure 1, Kaplan-Meier analysis showed no significant difference in the composite of in-hospital all-cause mortality or ICU admission between RVD and no RVD groups (log-rank p=0.464).

At multivariable logistic regression analysis (online supplementary table 1), the significant association between PH and the composite of all-cause death or ICU admission remained after adjustment for age, sex, CXR severity score ≥4, high-sensitivity troponin T and PaO2/FiO2 on hospital admission (ORadj 4.98, 95% CI 1.24 to 19.94, p=0.023; C-statistic=0.889, H-L p=0.978).

Discussion

The main findings of our study are:

Among hospitalised patients with COVID-19 in a non-ICU setting, the observed prevalence of PH and RVD was 12.0% and 14.5%, respectively.

Patients with PH and RVD had more frequently a history of prior cardiac comorbidities; however, only patients with PH showed signs of more severe SARS-CoV-2 infection in terms of CXR lung damage, laboratory parameters, oxygenation status and need of NIV.

The composite of all-cause mortality or ICU admission was significantly higher among patients with PH (mainly driven by a higher mortality rate), and this association remained also after adjustment for selected covariates. Conversely, RVD was not associated with unfavourable in-hospital outcomes.

The association between severe acute respiratory failure and PH has been demonstrated by several studies, mainly focusing on critically ill patients treated in ICU setting.21–24 Secondary alterations of pulmonary vascular haemodynamics during acute respiratory distress syndrome (ARDS) are multifactorial, depending on hypoxia, vascular remodelling or compression by oedema or fibrosis, increased alveolar pressure, vasoconstriction, local thrombosis or pulmonary embolism, and reduced pulmonary compliance and use of PEEP.4 5 7 25 While the advanced stages of COVID-19 are characterised by severe ARDS and need of mechanical ventilation (and the mentioned pathophysiological mechanisms could be directly translated to such scenario), whether a less-advanced SARS-CoV-2 pneumonia could determine a significant change in pulmonary vascular haemodynamics leading to PH and RV involvement was unknown. In our study, the observed prevalence of PH and RVD among hospitalised non-ICU patients with confirmed COVID-19 was 12.0% and 14.5%, respectively. Of note, the cross-sectional nature of the study determined a systematic TTE assessment of unselected patients admitted to COVID-19 dedicated departments, hence limiting selection bias and allowing quantification of the actual prevalence of PH and RV involvement. As expected, the observed figures seem lower compared with previous studies exploring PH and RV failure among ARDS patients in ICU settings.22 26 27 Although the absence of positive-pressure ventilation-mediated changes in pulmonary haemodynamics could be implicated in the observed prevalence of PH and RVD in our population, most included patients fulfilled criteria of ARDS even though outside the ICU setting (median PaO2/FiO2 243 (132–314), bilateral lung infiltrates in 82.5% of patients).12 18 Therefore, the observed findings refer to a population with moderate–severe COVID-19, without critical lung involvement (requiring ICU admission) but also without mild SARS-CoV-2 pneumonia (likely not determining hospital admission).

A history of prior cardiac comorbidities was more frequent both in patients with PH and in those with RVD; similarly, biomarkers of cardiac involvement (high-sensitivity troponin T and NT-proBNP) were higher in both PH and RVD groups. Interestingly, however, only patients with PH had signs of more severe SARS-CoV-2 infection in terms of lung involvement (higher CXR severity score), laboratory assessment (lower lymphocyte count, higher D-dimer, interleukin-6, C reactive protein and lactate dehydrogenase), oxygenation status (lower SpO2/FiO2 and at TTE time) and need of NIV therapy. It could be speculated that while the presence of prior or concomitant cardiac disorders may be implicated in the occurrence of both PH and RVD in some patients with COVID-19, PH may better capture SARS-CoV-2-related cardiopulmonary dynamic changes. This could be particularly true in a non-critically ill patient population, where the initial pneumonia-related alterations in pulmonary vascular haemodynamics may determine only modest increase in pulmonary artery pressure, not enough to cause secondary RV failure. In addition, RV impairment has been more directly related to mechanical ventilation, a factor that is missing in our non-ICU population, thus eliminating a potential pathophysiological link between non-critical SARS-CoV-2 pneumonia and RV involvement.28 Despite being readily available at bedside, TAPSE and S’ wave may have not reached an adequate sensibility to identify also milder degrees of RV involvement in this cohort. Indeed, a recent study has identified RV longitudinal strain as a powerful predictor of adverse prognosis in patients with COVID-1911; in this cohort, TAPSE (but not S’ wave) identified patients with worse outcomes applying a cut-off of 23 mm, which is higher than that recommended for RV dysfunction diagnosis.11 15

In our study, only PH (and not RVD) had a significant impact on in-hospital all-cause mortality or ICU admission, driven by a higher mortality rate. This prognostic association remained also after adjustment for selected covariates that were significantly different between PH and no PH groups or that could impact on short-term prognosis of patients with COVID-19 (age, sex, CXR severity score ≥4, high-sensitivity troponin T and PaO2/FiO2 on hospital admission).

Interestingly, concomitant pulmonary thromboembolism was more frequently observed among patients with PH (77.8% of patients with available contrast-enhanced chest CT scan). The hypothesis that the observed laboratory findings in patients with PH (ie, higher D-dimer values) and the prognostic value of PH identification on TTE may be linked to concomitant pulmonary thromboembolism is intriguing, as preliminary reports suggest a high burden of thromboembolic complications during COVID-197 29 30; this hypothesis, however, should be substantiated with further dedicated studies.

Our study had an observational nature and, therefore, had all the usual limitations associated with this design. Furthermore, no independent adjudication of clinical events was performed; study endpoints were, however, hard clinical outcomes at low risk of assessment bias. The absence of core-laboratory analysis of echocardiographic data could have impacted on the observed prevalence of PH and RVD and, hence, on subsequent study findings. Another study limitation is the lack of a control population, since a comparison with a similar cohort of patients with non-SARS-CoV-2-related pneumonia could have allowed understanding of whether the observed prevalence of PH and RVD is expected (based on age, comorbidities and presence of pneumonia) or higher than expected (because of SARS-CoV-2-specific mechanisms). Moreover, the present study focused on PH and RVD only, not exploring other potential mechanisms and types of cardiac injury during COVID-19.

Conclusions

Among hospitalised non-ICU patients with COVID-19, the prevalence of PH and RVD was 12.0% and 14.5%, respectively. Both patients with PH and RVD presented more frequently with prior cardiac comorbidities. Only PH was associated with clinical, imaging and laboratory findings of more severe COVID-19 and with worse in-hospital clinical outcomes.

COVID-19 is characterised by prominent lung injury with associated thromboembolic phenomena and signs of myocardial damage.

Among hospitalised non-critically ill patients with COVID-19, pulmonary hypertension (PH) is associated with signs of more severe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and with worse in-hospital clinical outcome.

Identification of PH could be prognostically relevant in hospitalised patients with COVID-19 and signs of more severe SARS-CoV-2 infection.